세계의 폐동맥 고혈압 시장(2022년)

“Pulmonary Arterial Hypertension Global Market Report 2022” from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global pulmonary arterial hypertension market.

This report focuses on pulmonary arterial hypertension market which is experiencing strong growth. The report gives a guide to the pulmonary arterial hypertension market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.

• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.

• Create regional and country strategies on the basis of local data and analysis.

• Identify growth segments for investment.

• Outperform competitors using forecast data and the drivers and trends shaping the market.

• Understand customers based on the latest market research findings.

• Benchmark performance against key competitors.

• Utilize the relationships between key data sets for superior strategizing.

• Suitable for supporting your internal and external presentations with reliable high quality data and analysis

• Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Where is the largest and fastest growing market for the pulmonary arterial hypertension? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The Pulmonary Arterial Hypertension market global report” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pulmonary arterial hypertension market, and compares it with other markets.

• The market characteristics section of the report defines and explains the market.

• The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.

• Market segmentations break down market into sub markets.

• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.

• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

• The pulmonary arterial hypertension market section of the report gives context. It compares the pulmonary arterial hypertension market with other segments of the pulmonary arterial hypertension market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, pulmonary arterial hypertension indicators comparison.

Scope

Markets Covered:

• 1) By Drug Class: Endothelin Receptor Antagonists (ERAs); PDE-5 Inhibitors; Prostacyclin and Prostacyclin Analogs; SGC Stimulators

• 2) By Route of Administration: Oral; Intravenous/ subcutaneous; Inhalational

• 3) By Distribution channel: Retail; Online

• Companies Mentioned: United Therapeutics Corporation; Bayer AG; Gilead Sciences, Inc.; Johnson & Johnson; GlaxoSmithKline

• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

• Time series: Five years historic and ten years forecast.

• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Executive Summary

Major players in the pulmonary arterial hypertension market are: United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc, Natco Pharma Ltd, Zydus Pharmaceutical USA, and Liquidia Technologies Inc.

The global pulmonary arterial hypertension market is expected to grow from $6.59 billion in 2021 to $7.04 billion in 2022 at a compound annual growth rate (CAGR) of 6.85%. The pulmonary arterial hypertension market is expected to reach $9.65 billion in 2026 at a CAGR of 8.22%.

The pulmonary arterial hypertension market consists of sales of drugs by entities (organizations, sole proprietors, partnerships) that are used in the treatment of pulmonary arterial hypertension disease, which is a rare progressive disorder characterized by high blood pressure in the arteries of the lungs. During this medical condition walls of the pulmonary arteries thicken and stiffen, making it very difficult for blood to flow through the lungs. The pulmonary arterial hypertension drugs relax the muscles in the wall of the blood vessels or increase the blood flow through the lungs or reverse the effect of the substance in the walls of blood vessels, which caused them to narrow.

The main types of pulmonary arterial hypertension drug classes are endothelin receptor antagonists (ERAS), PDE-5 inhibitors, prostacyclin and prostacyclin analogs, and SGC stimulators. Endothelin receptor antagonists (ERAs) are a form of targeted medication that is used to treat pulmonary hypertension in patients (PH). Targeted medicines can help to reduce the course of PH and potentially reverse some of the heart and lung damage. The drugs are administered through oral, intravenous/ subcutaneous. inhalational modes and distributed through retail and online channels.

North America was the largest region in the pulmonary arterial hypertension market in 2021. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market. The increasing prevalence of PAH diseases and related hospitalization of patients for treatment is expected to boost the demand for relevant drugs during the forecast period. According to a study published in National Organization for Rare Disorders, Inc., the new cases of PAH are estimated to occur in one to two individuals per million each year in the USA, which equates to 500-1000 new cases each year, and Europe is expected to have similar incidence rates.

Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drugs sector are focusing on developing new medicines to improvise and cure the diseases. In March 2019, Sandoz, a Switzerland-based company specializing in high-quality affordable medications announced the first fully substitutable AP-rated generic version of Remodulin treprostinil injection in the USA sold by United Therapeutics Corporation. Treprostinil Injection is used to reduce the symptoms of Pulmonary Arterial Hypertension and has the same active ingredient, strengths, dose form, and inactive ingredients as Remodulin® (treprostinil), and it is provided to patients and clinicians with the same level of service and support but at a lower cost.

In September 2021, Merck Group a German-based multinational science and technology company that specializes in healthcare and life sciences solutions acquired Acceleron Pharma for $11 billion. Through this acquisition, Merck will obtain ownership of Acceleron's portfolio of rare illness therapies, including sotatercept, a Phase III pulmonary arterial hypertension (PAH) medication and also puts the company at the forefront of rare disease-focused companies. Acceleron Pharma is a US-based company committed to the research, development, and commercialization of therapies for the treatment of critical and uncommon conditions such as pulmonary arterial hypertension.

The countries covered in the pulmonary arterial hypertension market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Table of Contents

1. Executive Summary

2. Pulmonary Arterial Hypertension Market Characteristics

3. Pulmonary Arterial Hypertension Market Trends And Strategies

4. Impact Of COVID-19 On Pulmonary Arterial Hypertension

5. Pulmonary Arterial Hypertension Market Size And Growth

• 5.1. Global Pulmonary Arterial Hypertension Historic Market, 2016-2021, $ Billion
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints On The Market
• 5.2. Global Pulmonary Arterial Hypertension Forecast Market, 2021-2026F, 2031F, $ Billion
  • 5.2.1. Drivers Of The Market
  • 5.2.2. Restraints On the Market

6. Pulmonary Arterial Hypertension Market Segmentation

• 6.1. Global Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators
• 6.2. Global Pulmonary Arterial Hypertension Market, Segmentation By Route of Administration, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• Oral
• Intravenous/ subcutaneous
• Inhalational
• 6.3. Global Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• Retail
• Online

7. Pulmonary Arterial Hypertension Market Regional And Country Analysis

• 7.1. Global Pulmonary Arterial Hypertension Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 7.2. Global Pulmonary Arterial Hypertension Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

8. Asia-Pacific Pulmonary Arterial Hypertension Market

• 8.1. Asia-Pacific Pulmonary Arterial Hypertension Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 8.3. Asia-Pacific Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

9. China Pulmonary Arterial Hypertension Market

• 9.1. China Pulmonary Arterial Hypertension Market Overview
• 9.2. China Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
• 9.3. China Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

10. India Pulmonary Arterial Hypertension Market

• 10.1. India Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 10.2. India Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

11. Japan Pulmonary Arterial Hypertension Market

• 11.1. Japan Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 11.2. Japan Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

12. Australia Pulmonary Arterial Hypertension Market

• 12.1. Australia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 12.2. Australia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

13. Indonesia Pulmonary Arterial Hypertension Market

• 13.1. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 13.2. Indonesia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

14. South Korea Pulmonary Arterial Hypertension Market

• 14.1. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 14.2. South Korea Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

15. Western Europe Pulmonary Arterial Hypertension Market

• 15.1. Western Europe Pulmonary Arterial Hypertension Market Overview
• 15.2. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 15.3. Western Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

16. UK Pulmonary Arterial Hypertension Market

• 16.1. UK Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 16.2. UK Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

17. Germany Pulmonary Arterial Hypertension Market

• 17.1. Germany Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 17.2. Germany Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

18. France Pulmonary Arterial Hypertension Market

• 18.4. France Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 18.5. France Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

19. Eastern Europe Pulmonary Arterial Hypertension Market

• 19.1. Eastern Europe Pulmonary Arterial Hypertension Market Overview
• 19.2. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 19.3. Eastern Europe Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

20. Russia Pulmonary Arterial Hypertension Market

• 20.1. Russia Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 20.2. Russia Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

21. North America Pulmonary Arterial Hypertension Market

• 21.1. North America Pulmonary Arterial Hypertension Market Overview
• 21.2. North America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 21.3. North America Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

22. USA Pulmonary Arterial Hypertension Market

• 22.1. USA Pulmonary Arterial Hypertension Market Overview
• 22.2. USA Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 22.3. USA Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

23. South America Pulmonary Arterial Hypertension Market

• 23.1. South America Pulmonary Arterial Hypertension Market Overview
• 23.2. South America Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 23.3. South America Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

24. Brazil Pulmonary Arterial Hypertension Market

• 24.1. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 24.2. Brazil Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

25. Middle East Pulmonary Arterial Hypertension Market

• 25.1. Middle East Pulmonary Arterial Hypertension Market Overview
• 25.2. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 25.3. Middle East Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

26. Africa Pulmonary Arterial Hypertension Market

• 26.1. Africa Pulmonary Arterial Hypertension Market Overview
• 26.2. Africa Pulmonary Arterial Hypertension Market, Segmentation By Drug Class, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
• 26.3. Africa Pulmonary Arterial Hypertension Market, Segmentation By Distribution channel, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

27. Pulmonary Arterial Hypertension Market Competitive Landscape And Company Profiles

• 27.1. Pulmonary Arterial Hypertension Market Competitive Landscape
• 27.2. Pulmonary Arterial Hypertension Market Company Profiles
  • 27.2.1. United Therapeutics Corporation
    • 27.2.1.1. Overview
    • 27.2.1.2. Products and Services
    • 27.2.1.3. Strategy
    • 27.2.1.4. Financial Performance
  • 27.2.2. Bayer AG
    • 27.2.2.1. Overview
    • 27.2.2.2. Products and Services
    • 27.2.2.3. Strategy
    • 27.2.2.4. Financial Performance
  • 27.2.3. Gilead Sciences Inc.
    • 27.2.3.1. Overview
    • 27.2.3.2. Products and Services
    • 27.2.3.3. Strategy
    • 27.2.3.4. Financial Performance
  • 27.2.4. Johnson & Johnson
    • 27.2.4.1. Overview
    • 27.2.4.2. Products and Services
    • 27.2.4.3. Strategy
    • 27.2.4.4. Financial Performance
  • 27.2.5. GlaxoSmithKline
    • 27.2.5.1. Overview
    • 27.2.5.2. Products and Services
    • 27.2.5.3. Strategy
    • 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The Pulmonary Arterial Hypertension Market

29. Pulmonary Arterial Hypertension Market Future Outlook and Potential Analysis

30. Appendix

• 30.1. Abbreviations
• 30.2. Currencies
• 30.3. Research Inquiries
• 30.4. The Business Research Company
• 30.5. Copyright And Disclaimer